Shilpa Gupta, MD, Cleveland Clinic, details some of her latest research and describes the importance of multiple new initiatives, including AI modeling for improving prognosis in advanced bladder cancer, the KEYNOTE-992 and MAIN-CAV trials in progress, and mUC platinum-eligibility criteria.
AI Modeling, KEYNOTE-992, MAIN-CAV, and Platinum-Eligibility Criteria in Bladder Cancer
By Shilpa Gupta, MD - Last Updated: January 27, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.